CEA vaccines
ABSTRACTCarcinoembryonic antigen (CEA) is a glycosylated cell surface oncofetal protein involved in adhesion, proliferation, and migration that is highly upregulated in multiple carcinomas and has long been a promising target for cancer vaccination. This review summarizes the progress to date in the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2023.2291857 |
| _version_ | 1797352564247756800 |
|---|---|
| author | Anchit Bhagat Herbert K. Lyerly Michael A. Morse Zachary C. Hartman |
| author_facet | Anchit Bhagat Herbert K. Lyerly Michael A. Morse Zachary C. Hartman |
| author_sort | Anchit Bhagat |
| collection | DOAJ |
| description | ABSTRACTCarcinoembryonic antigen (CEA) is a glycosylated cell surface oncofetal protein involved in adhesion, proliferation, and migration that is highly upregulated in multiple carcinomas and has long been a promising target for cancer vaccination. This review summarizes the progress to date in the development of CEA vaccines, examining both pre-clinical and clinical studies across a variety of vaccine platforms that in aggregate, begin to reveal some critical insights. These studies demonstrate the ability of CEA vaccines to break immunologic tolerance and elicit CEA-specific immunity, which associates with improved clinical outcomes in select individuals. Approaches that have combined replicating viral vectors, with heterologous boosting and different adjuvant strategies have been particularly promising but, these early clinical trial results will require confirmatory studies. Collectively, these studies suggest that clinical efficacy likely depends upon harnessing a potent vaccine combination in an appropriate clinical setting to fully realize the potential of CEA vaccination. |
| first_indexed | 2024-03-08T13:17:25Z |
| format | Article |
| id | doaj.art-7f610e85ba744d38aad775de0f57cec3 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-08T13:17:25Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-7f610e85ba744d38aad775de0f57cec32024-01-18T04:54:12ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-12-0119310.1080/21645515.2023.2291857CEA vaccinesAnchit Bhagat0Herbert K. Lyerly1Michael A. Morse2Zachary C. Hartman3Department of Surgery, Division of Surgical Sciences, Duke University, Durham, NC, USADepartment of Surgery, Division of Surgical Sciences, Duke University, Durham, NC, USADepartment of Surgery, Division of Surgical Sciences, Duke University, Durham, NC, USADepartment of Surgery, Division of Surgical Sciences, Duke University, Durham, NC, USAABSTRACTCarcinoembryonic antigen (CEA) is a glycosylated cell surface oncofetal protein involved in adhesion, proliferation, and migration that is highly upregulated in multiple carcinomas and has long been a promising target for cancer vaccination. This review summarizes the progress to date in the development of CEA vaccines, examining both pre-clinical and clinical studies across a variety of vaccine platforms that in aggregate, begin to reveal some critical insights. These studies demonstrate the ability of CEA vaccines to break immunologic tolerance and elicit CEA-specific immunity, which associates with improved clinical outcomes in select individuals. Approaches that have combined replicating viral vectors, with heterologous boosting and different adjuvant strategies have been particularly promising but, these early clinical trial results will require confirmatory studies. Collectively, these studies suggest that clinical efficacy likely depends upon harnessing a potent vaccine combination in an appropriate clinical setting to fully realize the potential of CEA vaccination.https://www.tandfonline.com/doi/10.1080/21645515.2023.2291857Carcinoembryonic antigenCEAcancer vaccinesself-replicating RNAimmunotherapyheterologous boosting |
| spellingShingle | Anchit Bhagat Herbert K. Lyerly Michael A. Morse Zachary C. Hartman CEA vaccines Human Vaccines & Immunotherapeutics Carcinoembryonic antigen CEA cancer vaccines self-replicating RNA immunotherapy heterologous boosting |
| title | CEA vaccines |
| title_full | CEA vaccines |
| title_fullStr | CEA vaccines |
| title_full_unstemmed | CEA vaccines |
| title_short | CEA vaccines |
| title_sort | cea vaccines |
| topic | Carcinoembryonic antigen CEA cancer vaccines self-replicating RNA immunotherapy heterologous boosting |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2023.2291857 |
| work_keys_str_mv | AT anchitbhagat ceavaccines AT herbertklyerly ceavaccines AT michaelamorse ceavaccines AT zacharychartman ceavaccines |